Lixte Biotechnology (LIXT) Competitors $5.70 -0.31 (-5.16%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$5.78 +0.08 (+1.32%) As of 09/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIXT vs. XBIT, WHWK, QNCX, ABOS, ATRA, IMUX, OKYO, IRD, BYSI, and STROShould you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include XBiotech (XBIT), Whitehawk Therapeutics (WHWK), Quince Therapeutics (QNCX), Acumen Pharmaceuticals (ABOS), Atara Biotherapeutics (ATRA), Immunic (IMUX), OKYO Pharma (OKYO), Opus Genetics (IRD), BeyondSpring (BYSI), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry. Lixte Biotechnology vs. Its Competitors XBiotech Whitehawk Therapeutics Quince Therapeutics Acumen Pharmaceuticals Atara Biotherapeutics Immunic OKYO Pharma Opus Genetics BeyondSpring Sutro Biopharma XBiotech (NASDAQ:XBIT) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership. Do institutionals and insiders hold more shares of XBIT or LIXT? 55.7% of XBiotech shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 30.8% of XBiotech shares are held by insiders. Comparatively, 14.8% of Lixte Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer XBIT or LIXT? In the previous week, Lixte Biotechnology had 2 more articles in the media than XBiotech. MarketBeat recorded 4 mentions for Lixte Biotechnology and 2 mentions for XBiotech. XBiotech's average media sentiment score of 1.55 beat Lixte Biotechnology's score of 0.73 indicating that XBiotech is being referred to more favorably in the media. Company Overall Sentiment XBiotech Very Positive Lixte Biotechnology Positive Which has more volatility & risk, XBIT or LIXT? XBiotech has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Which has preferable valuation and earnings, XBIT or LIXT? Lixte Biotechnology has lower revenue, but higher earnings than XBiotech. Lixte Biotechnology is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXBiotech$4.01M20.68-$38.53M-$0.92-2.96Lixte BiotechnologyN/AN/A-$3.59M-$1.29-4.42 Is XBIT or LIXT more profitable? Lixte Biotechnology's return on equity of 0.00% beat XBiotech's return on equity.Company Net Margins Return on Equity Return on Assets XBiotechN/A -15.60% -14.64% Lixte Biotechnology N/A N/A -222.90% SummaryXBiotech beats Lixte Biotechnology on 8 of the 11 factors compared between the two stocks. Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIXT vs. The Competition Export to ExcelMetricLixte BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.39M$3.15B$5.80B$10.17BDividend YieldN/A2.32%5.73%4.61%P/E Ratio-4.4221.2474.8626.39Price / SalesN/A472.01544.60190.76Price / CashN/A44.4425.8129.91Price / Book-4.799.6413.256.28Net Income-$3.59M-$53.20M$3.29B$270.38M7 Day Performance18.75%0.07%0.07%1.89%1 Month Performance58.77%4.27%4.59%6.01%1 Year Performance179.41%9.62%72.95%25.26% Lixte Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIXTLixte Biotechnology0.883 of 5 stars$5.70-5.2%N/A+186.4%$27.39MN/A-4.424Short Interest ↓XBITXBiotech2.1489 of 5 stars$2.85+4.0%N/A-61.5%$86.13M$4.01M-3.07100News CoveragePositive NewsShort Interest ↓WHWKWhitehawk Therapeutics1.1828 of 5 stars$1.82+1.7%N/AN/A$85.78M$25.98M-30.3321QNCXQuince Therapeutics3.4408 of 5 stars$1.59+1.0%$8.14+413.7%+117.7%$85.13MN/A-1.4560ABOSAcumen Pharmaceuticals3.0402 of 5 stars$1.41-0.4%$7.00+398.2%-51.5%$85.10MN/A-0.6220Positive NewsATRAAtara Biotherapeutics4.437 of 5 stars$11.90-2.3%$21.00+76.5%+22.8%$83.57M$188.67M-27.67330Gap UpIMUXImmunic1.9879 of 5 stars$0.84+2.1%$8.33+887.4%-49.1%$83.06MN/A-0.9070OKYOOKYO Pharma2.2203 of 5 stars$2.18-1.4%$7.00+221.1%+102.9%$81.99MN/A0.007News CoverageShort Interest ↑IRDOpus Genetics2.4063 of 5 stars$1.37-2.4%$7.33+436.8%N/A$81.84M$10.99M-0.7114BYSIBeyondSpringN/A$2.01+5.7%N/A-18.7%$81.06M$1.75M0.0080STROSutro Biopharma3.9734 of 5 stars$0.95-2.9%$4.47+368.2%-80.3%$80.45M$62.04M-0.38240Analyst Upgrade Related Companies and Tools Related Companies XBIT Alternatives WHWK Alternatives QNCX Alternatives ABOS Alternatives ATRA Alternatives IMUX Alternatives OKYO Alternatives IRD Alternatives BYSI Alternatives STRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIXT) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | SponsoredThe End of Elon Musk…?Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LIXT Stock Alerts